Detalhe da pesquisa
1.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
2.
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(27): 1823-1840, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492991
3.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer
; 123(23): 4617-4630, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817190
4.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Cancer
; 122(21): 3327-3335, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27433944
5.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(4): 433-439, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749004
6.
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Blood Adv
; 7(4): 644-648, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36006441
7.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(5): 609, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913648